Insulet - PODD Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PODD shares.
View PODD analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued twelve-month target prices for Insulet's stock. Their PODD share price forecasts range from $260.00 to $350.00. On average, they expect the company's stock price to reach $317.82 in the next year. This suggests a possible upside of 2.2% from the stock's current price.
View analysts price targets for PODD or view top-rated stocks among Wall Street analysts.

Insulet's stock was trading at $294.39 at the start of the year. Since then, PODD stock has increased by 5.6% and is now trading at $310.98.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our PODD earnings forecast.

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Thursday, February, 23rd. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.31. The medical instruments supplier had revenue of $369.70 million for the quarter, compared to the consensus estimate of $331.73 million. Insulet had a net margin of 0.35% and a trailing twelve-month return on equity of 20.55%. Insulet's revenue for the quarter was up 20.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.42 EPS.

ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Goldman Sachs Future Health Care Equity ETF (GDOC), Fidelity Digital Health ETF (FDHT), Invesco Focused Discovery Growth ETF (IVDG), VictoryShares Nasdaq Next 50 ETF (QQQN), Harbor Health Care ETF (MEDI), BlackRock Future Innovators ETF (BFTR) and Hartford Large Cap Growth ETF (HFGO).

Insulet updated its first quarter 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $327.89 million-$336.76 million, compared to the consensus revenue estimate of $333.86 million.

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (4.45%), Clearbridge Investments LLC (2.30%), Moneta Group Investment Advisors LLC (1.87%), Geode Capital Management LLC (1.38%), Fred Alger Management LLC (0.81%) and Allspring Global Investments Holdings LLC (0.65%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, Dan Manea, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends.

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PODD stock can currently be purchased for approximately $310.98.

Insulet (NASDAQ:PODD) has a market capitalization of $21.63 billion and generates $1.31 billion in revenue each year. The medical instruments supplier earns $4.60 million in net income (profit) each year or $0.06 on an earnings per share basis.

The company employs 2,600 workers across the globe.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.